A major portion of the article is regarding diabetes management but relevance for Unilife is how Sanofi plans to utilize these key learnings (from diabetes case study) for management of other diseases and launch of new drugs.
IMHO…There are several themes in the article that reflect how Unilife’s products are aligned with Sanofi’s strategy regarding Patient centricity, adherence, outcomes measurement data, etc. May be this is where some of Alan’s quotes are derived from (regarding industry trends) J
UNS Price at posting:
88.0¢ Sentiment: Buy Disclosure: Held